INSM · INSMED Inc · Webcasts, Transcripts & Audio
$123.82
+2.66 (+2.20%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$27.12B
Shares
219.38M
Volume · Nov 16
1.05M
Avg daily vol (3M)
2.77M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
INSMED Inc Webcasts
Earnings calls, investor updates, investor days and conferences for INSMED Inc (INSM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-01
INSMED Inc (INSM) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-16
INSMED Inc (INSM) November 16, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-29
INSMED Inc (INSM) Q3 2026 Earnings Call Transcript
Confident tone
TPIP clinical development
Brinsupri commercial momentum
Brinsupri geographic expansion
Revenue
$524.43M
▲ 268.4% YoY Diluted EPS
$-0.46
Gross margin
85.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
INSMED Inc (INSM) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
INSMED Inc (INSM) Q2 2026 Earnings Call Transcript
Confident tone
Brinsupri commercial launch
Revenue guidance raise
Raised peak sales estimates
Revenue
$425.49M
▲ 296.1% YoY Diluted EPS
$-0.06
Gross margin
84.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
INSMED Inc (INSM) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-20
INSMED Inc (INSM) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
INSMED Inc (INSM) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
INSMED Inc (INSM) Q1 2026 Earnings Call Transcript
Confident tone
BRINSUPRI Commercial Launch
Bronchiectasis Diagnosis Expansion / Disease Awareness
TPIP Phase III Development
Revenue
$305.96M
▲ 229.6% YoY Diluted EPS
$-0.76
Gross margin
84.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
INSMED Inc (INSM) Q4 2025 Earnings Call Transcript
Revenue
$263.84M*
▲ 152.6% YoY Gross margin
83.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
INSMED Inc (INSM) Q3 2025 Earnings Call Transcript
Confident tone
BRINSUPRI U.S. launch
Payer access and reimbursement
BiRCh Phase II in CRS without nasal polyps
Revenue
$142.34M
▲ 52.4% YoY Diluted EPS
$-1.75
Gross margin
79.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
INSMED Inc (INSM) Q2 2025 Earnings Call Transcript
Confident tone
Brensocatib U.S. launch and label/PDUFA
TPIP Phase III planning across PAH, PH-ILD, IPF
Pipeline label-expansion studies (BiRCh, CEDAR)
Revenue
$107.42M
▲ 18.9% YoY Diluted EPS
$-1.70
Gross margin
73.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
INSMED Inc (INSM) Q1 2025 Earnings Call Transcript
Confident tone
Brensocatib FDA review and bronchiectasis launch readiness
TPIP Phase 2 in PAH
ARIKAYCE commercial performance and ENCORE trial
Revenue
$92.82M
▲ 22.9% YoY Diluted EPS
$-1.42
Gross margin
77.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
INSMED Inc (INSM) Q4 2024 Earnings Call Transcript
Confident tone
Brensocatib launch readiness
TPIP clinical development
ARIKAYCE commercial performance
Revenue
$104.44M*
▲ 24.8% YoY Gross margin
75.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
INSMED Inc (INSM) Q3 2024 Earnings Call Transcript
Confident tone
Brensocatib NDA and launch preparation
TPIP in PAH and PH-ILD
ARIKAYCE commercial performance and ENCORE trial
Revenue
$93.42M
▲ 18.2% YoY Diluted EPS
$-1.27
Gross margin
77.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
INSMED Inc (INSM) Q2 2024 Earnings Call
Revenue
$90.34M
▲ 17% YoY Diluted EPS
$-1.94
Gross margin
76.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
INSMED Inc (INSM) Q1 2024 Earnings Call Transcript
Confident tone
TPIP PH-ILD Phase II safety results
TPIP PAH blinded Phase II data
Brensocatib ASPEN Phase III readout
Revenue
$75.50M
▲ 15.8% YoY Diluted EPS
$-1.06
Gross margin
76.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
INSMED Inc (INSM) Q4 2023 Earnings Call Transcript
Confident tone
Brensocatib (ASPEN readout) and bronchiectasis opportunity
TPIP program in PAH and PH-ILD
Regulatory pathway and FDA engagement
Revenue
$83.69M*
▲ 41.1% YoY Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
INSMED Inc (INSM) Q3 2023 Earnings Call Transcript
Revenue
$79.07M
▲ 16.7% YoY Diluted EPS
$-1.11
Gross margin
78.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
INSMED Inc (INSM) Q2 2023 Earnings Call Transcript
Revenue
$77.23M
▲ 18.4% YoY Diluted EPS
$-1.78
Gross margin
78.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
INSMED Inc (INSM) Q1 2023 Earnings Call Transcript
Revenue
$65.21M
▲ 22.8% YoY Diluted EPS
$-1.17
Gross margin
78.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
INSMED Inc (INSM) Q4 2022 Earnings Call Transcript
Revenue
$59.30M*
▲ 5.7% YoY Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
INSMED Inc (INSM) Q3 2022 Earnings Call Transcript
Revenue
$67.73M
▲ 44.9% YoY Diluted EPS
$-1.09
Gross margin
80.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
INSMED Inc (INSM) Q2 2022 Earnings Call Transcript
Revenue
$65.22M
▲ 43.8% YoY Diluted EPS
$-0.80
Gross margin
74.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
INSMED Inc (INSM) Q1 2022 Earnings Call Transcript
Revenue
$53.11M
▲ 32.1% YoY Diluted EPS
$-0.80
Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
INSMED Inc (INSM) Q4 2021 Earnings Call Transcript
Revenue
$56.12M*
▲ 35.5% YoY Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
INSMED Inc (INSM) Q3 2021 Earnings Call Transcript
Revenue
$46.76M
▲ 7.1% YoY Diluted EPS
$-0.96
Gross margin
78.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
INSMED Inc (INSM) Q2 2021 Earnings Call Transcript
Revenue
$45.37M
▲ 6.8% YoY Diluted EPS
$-1.07
Gross margin
76.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
INSMED Inc (INSM) Q1 2021 Earnings Call Transcript
Revenue
$40.21M
▲ 9.1% YoY Diluted EPS
$-0.89
Gross margin
75.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
INSMED Inc (INSM) Q4 2020 Earnings Call Transcript
Revenue
$41.41M*
▼ 9.4% YoY Gross margin
73.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
INSMED Inc (INSM) Q3 2020 Earnings Call Transcript
Revenue
$43.64M
▲ 12.2% YoY Diluted EPS
$-0.63
Gross margin
75.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
INSMED Inc (INSM) Q2 2020 Earnings Call Transcript
Revenue
$42.49M
▲ 41.8% YoY Diluted EPS
$-0.64
Gross margin
76.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
INSMED Inc (INSM) Q1 2020 Earnings Call Transcript
Revenue
$36.86M
▲ 68.3% YoY Gross margin
77.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
INSMED Inc (INSM) Q4 2019 Earnings Call
Revenue
$45.71M
▲ 364.7% YoY Gross margin
81.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–34 of 34 webcasts
Key facts
CIK
1104506
CUSIP
457669307
13F (30d)
535 filings
488 filers
Visit website
Investor relations